SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 381.52 |
| Enterprise Value ($M) | 407.24 |
| Book Value ($M) | 39.67 |
| Book Value / Share | 0.73 |
| Price / Book | 9.62 |
| NCAV ($M) | -52.43 |
| NCAV / Share | -0.97 |
| Price / NCAV | -7.28 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.06 |
| Return on Assets (ROA) | -0.70 |
| Return on Equity (ROE) | -2.16 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.47 |
| Current Ratio | 2.53 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 86.03 |
| Assets | 178.13 |
| Liabilities | 138.46 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 23.61 |
| Operating Income | -87.00 |
| Net Income | -105.51 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -69.67 |
| Cash from Investing | -22.16 |
| Cash from Financing | 82.11 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Nantahala Capital Management, LLC | 4.38 | ||
| 13G | Adage Capital Management, L.P. | 6.84 | ||
| 13G/A | BlackRock, Inc. | 7.60 | 69.29 | |
| 13G | Woodline Partners LP | 7.70 | ||
| 13G/A | Vanguard Group Inc | 5.23 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 79,881 | 363,800 | 21.96 | |
| 82,944 | 271,228 | 30.58 | |
| 53,019 | 475,981 | 11.14 | |
| 59,211 | 348,840 | 16.97 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| XERS – Xeris Biopharma Holdings, Inc. | XLO – Xilio Therapeutics, Inc. |
| YMAB – Y-mAbs Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io